Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Objectives: To quantify differences in control of glycemia (primary objective) and the
secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or
placebo added to pre-existing therapy with liraglutide and metformin
Phase:
Phase 3
Details
Lead Sponsor:
Michael A. Nauck
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Hypoglycemic Agents Incretins Liraglutide Metformin Sitagliptin Phosphate